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We report a case of lower respiratory tract infection with human bocavirus 1 (HBoV1) in an 25 
immunodeficient 6-month-old boy leading to respiratory failure with fatal outcome. PCR of 26 
serum/tracheal secretions revealed exceptionally high HBoV1-DNA levels and immunoassays 27 
showed seroconversion indicating an acute primary HBoV1 infection. All assays for other 28 
pathogens were negative, strongly suggesting that HBoV1 was the causative agent in this 29 
case.  30 
Background 31 
Human bocavirus (HBoV) 1 is a recently identified viral agent that belongs to the family of 32 
Parvoviridae and comprises a non-enveloped capsid with a linear single-stranded DNA 33 
genome [1]. Viral DNA has been detected mainly in nasopharyngeal secretions, and in serum 34 
or blood samples of younger children with upper or lower respiratory tract infections (RTI). 35 
Besides HBoV1, which is predominantly detected in the respiratory tract, three other 36 
bocaviruses, HBoV2 – 4, are mainly found in stool.   37 
Detection of HBoV1 DNA in airway samples of children with RTI is frequently combined 38 
with other viruses or bacteria because HBoV1 persists and is shed for a prolonged period. 39 
This makes interpretation of a PCR-positive test result difficult. The high detection rate of 40 
multiple respiratory viruses in an airway specimen, and the presence of HBoV1 DNA in 41 
asymptomatic children, thereby complicate the diagnosis of acute HBoV1 infections [2]. In 42 
addition to detection of HBoV1 DNA in airway samples, other diagnostic methods, such as 43 
serology, should be used. With accurate diagnostic methods, acute HBoV1 infection has been 44 
shown to cause mild to life-threatening RTIs. Due to the lack of an animal model, the Koch’s 45 
postulates have not been formally fulfilled, thus proving clinical relevance is challenging. 46 
 5 
Life-threatening infections are rare. Here we present a case of HBoV1 lower RTI, diagnosed 47 
by both PCR and serology, leading to severe respiratory failure with fatal outcome in an 48 
immunodeficient child.  49 
 50 
Case presentation 51 
A six-month-old boy, the first child of consanguineous parents, was transferred from Dubai, 52 
United Arab Emirates, to the University Hospital Heidelberg, Germany, for further diagnostic 53 
workup of an unspecified syndrome including failure to thrive, distinct psychomotor 54 
retardation, multiple osseous malformations, microcephaly due to cerebral atrophy, blindness, 55 
and symptoms of an acute hemolytic uremic syndrome. Shortly after admission, a T-cell 56 
defect was diagnosed and whole-exon screening identified a homozygous mutation in the NIN 57 
gene which codes for Ninein, a protein crucial for mitosis. The NIN gene mutation was 58 
regarded as the cause of the complex syndrome. The cause of the immunodeficiency found in 59 
our patient was an impaired cytokine response in combination with insufficient formation of 60 
antigen-presenting cells to T lymphocyte synapses leading to a functional T-cell deficiency. 61 
Because of feeding difficulties and significant dysphagia, a percutaneous gastrostomy tube as 62 
well as a Hickman line were placed. The hemolytic uremic syndrome was treated with 63 
eculizumab; however, proteinuria and oliguria persisted and required high doses of diuretics. 64 
About ten days after admission, the boy developed pneumonia and was transferred to the 65 
intensive care unit where he had to be intubated, and was mechanically ventilated. He 66 
developed an acute respiratory distress syndrome (ARDS) with multiple critical 67 
deteriorations. One week after admission, an initial radiograph was performed in the context 68 
of the surgery for a Hickman line and a gastrostomy tube. He did not show signs of a 69 
preceding lung injury (Fig. 1). Mechanical ventilation was difficult with an FiO2 of 1.0, high 70 
inspiratory pressures up to 40/11 mbar, and intermittent use of high frequency oscillation and 71 
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inhaled nitric oxide. Tracheostomy was performed after six weeks of mechanical ventilation. 72 
Because of atelectasis, pulmonary secretion, and bronchospasm, the mechanical ventilation 73 
had to be intensified several times. Elevated CRP values (average 92.4 mg/l, peak 221.7 mg/l, 74 
normal <5 mg/l) were first noted one week prior to intubation and mechanical ventilation, and 75 
did not normalize over the next four months. This prompted antibiotic treatment with different 76 
combinations of cefotaxime, meropenem, ciprofloxacin, teicoplanin, linezolid, and 77 
erythromycin with no clinical effect. Apart from Staphylococcus epidermidis detected in a 78 
single blood culture, bacterial as well as fungal cultures and PCR for atypical microorganisms 79 
in tracheal secretions were always negative. Tracheal secretions were also tested in a real time 80 
multiplex respiratory PCR (Fast Track Diagnostics respiratory pathogens 21, Luxembourg) 81 
for influenza A virus including H1N1, influenza B virus, rhinovirus, respiratory syncytial 82 
virus, bocavirus, adenovirus, parainfluenza virus 1 through 4, four coronaviruses (NL63, 83 
229E, OC43, HKU1), parechovirus, enterovirus, human metapneumovirus A/B and 84 
Mycoplasma pneumoniae. Additionally, these samples were also tested for herpes simplex 85 
virus and varicella zoster virus DNA by in-house PCR and for bacteria and fungi by culture. 86 
Human bocavirus 1 (HBoV1) was the only pathogen detected in tracheal secretions. All serial 87 
tracheal secretions were positive for HBoV1 DNA, which was present in high copy numbers 88 
in some samples (Fig. 2A). The highest viral load in respiratory samples of 3.1 x 109 89 
copies/ml was detected about day 20 of hospitalisation, one week after pneumonia was 90 
diagnosed and mechanical ventilation initiated. The viral load decreased slowly in respiratory 91 
samples but DNA was detectable for several months. Blood was taken from the patient once 92 
per week and HBoV1 DNA was detectable in serum for 50 days with a peak of 2.0 x 103 93 
copies/ml. The specificity of the real-time PCR was confirmed with a qPCR and an in-house 94 
PCR followed by DNA sequence analysis of the amplified product. The qPCR assays were 95 
performed using the 1xSensiMix SYBR No-ROX Kit (Bioline Reagents Ltd, London, UK) 96 
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with HBoV1-specific primers (forward primer 5′-CCTATATAACCTGCTGCACTTCCT-3′, 97 
reverse primer 5′- AAGCCATAGTAGACTCACCACAAG-3′).  98 
The complete VP1 gene (2016 bp) of the HBoV1 genome was amplified by an in-house PCR 99 
assay including the HBoV1-specific primers (forward primer 5′- 100 
GTTACGTCTCGAAGATTACAACACTTTATTGATGTTTG-3′, reverse primer 5′-101 
GTTACGTCTCAGCAGATGCCTCCAATTAAGAGACA-3′). The PCR product was 102 
purified and subsequently sequenced. The sequence (accession no. MG680946) was then 103 
aligned with different HBoV strains reported in GenBank and subjected to a phylogenetic 104 
analysis (Fig. 3). This confirmed a 99% identity of the study sample with HBoV1, thus 105 
verifying the specificity of the multiplex respiratory PCR, the qPCR and the immunoassays. 106 
Moreover, the phylogenetic analysis revealed a close relationship to a previously reported 107 
HBoV1 isolate from Egypt [3] (GB accession no. KU557404.1, as shown in Fig. 3). By 108 
following the course of infection over a period of four months, we detected the emergence 109 
and persistence of a mutation at amino acid position 590 (VP1 numbering) that results in an 110 
amino-acid change from threonine to serine.  111 
HBoV1-specific IgG and IgM were measured by highly sensitive and specific competition 112 
immunoassays based on HBoV1-like particles [4, 5]. Both IgG and IgM antibodies against 113 
HBoV1 were detected and seroconversion was observed (Fig. 2B), indicating an acute 114 
HBoV1 infection. Thus, HBoV1 was considered the most likely cause of ARDS. The patient 115 
died of multi-organ failure following four months of mechanical ventilation. 116 
 117 
Discussion and conclusions 118 
Human bocavirus 1 (HBoV1) was discovered in 2005 by Allander et al. in respiratory 119 
secretions [1] and is increasingly recognized as a cause of pediatric respiratory tract infections 120 
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worldwide [2, 6, 7]. By PCR of airway samples, HBoV1 DNA has been detected in 2-20% of 121 
children with respiratory tract infection, whereas 40-75% of the HBoV1 DNA-positive 122 
patients show co-detections with other respiratory pathogens [8, 9]. 123 
However, it is important to acknowledge that almost all routine testing and published studies 124 
of HBoV1 infections rely on only PCR testing of respiratory secretions. HBoV1 DNA can by 125 
sensitive PCRs be detected for months or even up to a year after acute infection, leading to 126 
co-detections and false clinical diagnoses — and thereby, inaccurate disease associations [10 - 127 
13]. Mere qualitative PCR is therefore not an adequate method for diagnosing acute HBoV1 128 
infections, instead a combination of other diagnostic means including qPCR of respiratory 129 
samples and serum, as well as serology should be applied [4, 14].  130 
By utilizing accurate diagnostics, increasing evidence has been gathered of HBoV1 being the 131 
cause of mild to severe upper and lower respiratory tract infections in children over 6 months 132 
of age [6, 7]. HBoV1 may cause also life-threatening complications of lower respiratory tract 133 
infection including emphysema, pneumomediastinum, pneumothorax and acute respiratory 134 
failure [15 - 18]. In addition, both Sadeghi et al. [19] and Krakau et al. [20] described 135 
immunocompromised adult patients suffering from an advanced myelodysplastic syndrome 136 
with severe HBoV1 pneumonia with fatal outcome. Further fatal cases associated with 137 
HBoV1 infection were described in an adult and a pediatric patient with underlying lung 138 
diseases [21, 22]. The need for ventilator support for four months reflecting the extensive lung 139 
damage is perfectly explained by the severe ARDS leading to lung fibrosis, impaired gas 140 
exchange and eventually death of the patient. Most of the damage to the lungs of patients that 141 
do not recover from ARDS is caused by pulmonary inflammation and interstitial fibrosis. It 142 
has been shown that HBoV1 infection of in vitro airway epithelium cultures inhibits apoptosis 143 
and induces pyroptotic cell death, resulting in tissue injury and inflammation [23, 24]. 144 
Persistent HBoV1 infection of the lungs in immunocompromised children may thus lead to 145 
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lung tissue injury. It can therefore be hypothesized that persistent HBoV1 infection in this 146 
child directly damaged the alveolar tissue.  147 
Nevertheless, the significance of HBoV1 infection as a cause of death, as described in this 148 
case of an immunodeficient child, is not easy to determine. However, viral DNA of 149 
exceptionally high copy numbers of 5x109 copies/ml was observed in tracheal secretions at 150 
the same time as it occurred in serum, pointing to an acute HBoV1 infection. In general, acute 151 
HBoV1 infection is accompanied by the presence of viral DNA in serum [4]. After atypical 152 
hemolytic-uremic syndrome had been diagnosed at the age of three months, eculizumab was 153 
given five times with approximately three weeks between each application. The last dose was 154 
applied 18 days before the respiratory decompensation. It is tempting to speculate that the 155 
very high viral load reflects the unusually complicated clinical course and the 156 
immunocompromised status of the patient. High viral loads of HBoV1 are associated with 157 
respiratory symptoms whereas low viral loads mostly indicate longitudinal asymptomatic 158 
shedding [2, 4, 6, 14, 25, 26]. Detection of HBoV1 DNA in serum has further been more 159 
tightly linked to symptoms than DNA in respiratory samples. The functional T-cell defect in 160 
our case is regularly found in Schimke immuno-osseous dysplasia that was initially suspected 161 
but ruled out genetically. Other cases with severe HBoV1 infection in patients with T-cell 162 
defect or immunodeficiency have been reported previously [10, 19, 27, 28].   163 
High HBoV1 DNA copy numbers in airway samples, short viremic phase, detection of 164 
HBoV1-specific IgM and seroconversion of IgG antibodies have been shown to be accurate 165 
diagnostic markers in children with acute HBoV1-induced respiratory illness and can thereby 166 
separate acute infection from asymptomatic virus shedding [4]. The usefulness of the applied 167 
serology has been documented in studies of children with acute wheezing or with community-168 
aquired pneumonia [4, 29, 30]. HBoV1 IgM positivity correlates with both HBoV1 viremia 169 
and seroconversion of IgG in paired serum samples, whereas healthy subjects are generally 170 
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IgM negative with stable IgG absorbance levels [4]. While in this case, multiplex PCR for 19 171 
other respiratory viruses and mycoplasma was negative, the course of the disease perfectly 172 
matched a primary infection by HBoV1, supported by serology and detection of HBoV1 DNA 173 
in serum.  174 
The emergence and persistence of a mutation at amino acid position 590 that resulted in an 175 
amino-acid change from threonine to serine reflects either (i) a mixed primary infection with 176 
two HBoV1 variants, where one dominates over time, (ii) a secondary infection with a 177 
different HBoV1 variant, as hypothesized in Martin et al. [12], or (iii) the occurrence of a de 178 
novo mutation that fostered clonal selection. Further time-course studies with more patients 179 
and the use of deep sequencing approaches are required to unanimously resolve these 180 
possibilities.  181 
This report illustrates that blood sampling is important for linking HBoV1 with disease, and it 182 
indicates that HBoV1 should be considered in severe respiratory tract disease in children. 183 
HBoV1 is the most probable cause of respiratory tract disease if the patient has a high viral 184 
load in respiratory samples accompanied by viremia, if HBoV1 is the only pathogen detected, 185 
and if an acute primary HBoV1 infection is diagnosed by serological testing [4, 8]. We 186 
detected HBoV1 DNA in both respiratory and serum samples. Moreover, the serologic results 187 
indicate that this child had an acute primary HBoV1 infection. The dramatic increase of 188 
HBoV1 load in tracheal secretions and viral dissemination most likely resulted from a 189 
progressive impairment of cellular immunity. The observation that all other viral and 190 
microbiological assays were negative, strongly suggest that HBoV1 was the causative agent 191 
of respiratory failure and death in the present case. 192 
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Fig. 1.  309 




Fig. 2. 314 
HBoV1 diagnostic findings. A) Detection of HBoV1 DNA in tracheal secretions and serum. 315 







Fig. 3. 322 
Maximum likelihood phylogenetic consensus tree for the VP ORF nucleotide sequence of the 323 
HBoV1 isolate (V1445149) studied here. The numbers next to the nodes indicate the value of 324 
500 bootstrap analyses. To root the tree, an outgroup of the indicated closely related members 325 
of the genus Bocaparvovirus was defined. Only bootstrap values higher than 50% are 326 
presented. Codon positions included were 1st+2nd+3rd+noncoding. Evolutionary analyses 327 
were conducted in MEGA 7.0.26. 328 
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